These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 15954910

  • 21. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
    Griffiths J, Mills MT, Ong AC.
    BMJ Open; 2020 Jan 09; 10(1):e032620. PubMed ID: 31924636
    [Abstract] [Full Text] [Related]

  • 22. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease.
    King BF, Reed JE, Bergstralh EJ, Sheedy PF, Torres VE.
    J Am Soc Nephrol; 2000 Aug 09; 11(8):1505-1511. PubMed ID: 10906164
    [Abstract] [Full Text] [Related]

  • 23. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
    van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP.
    Gastroenterology; 2009 Nov 09; 137(5):1661-8.e1-2. PubMed ID: 19646443
    [Abstract] [Full Text] [Related]

  • 24. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
    Neijenhuis MK, Gevers TJ, Nevens F, Hogan MC, Torres VE, Kievit W, Drenth JP.
    Aliment Pharmacol Ther; 2015 Sep 09; 42(5):591-8. PubMed ID: 26129925
    [Abstract] [Full Text] [Related]

  • 25. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
    Seliger SL, Abebe KZ, Hallows KR, Miskulin DC, Perrone RD, Watnick T, Bae KT.
    Am J Nephrol; 2018 Sep 09; 47(5):352-360. PubMed ID: 29779024
    [Abstract] [Full Text] [Related]

  • 26. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
    Kidney Int; 2003 Sep 09; 64(3):1035-45. PubMed ID: 12911554
    [Abstract] [Full Text] [Related]

  • 27. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N, Cortinovis M, Remuzzi G.
    G Ital Nefrol; 2016 Sep 09; 33(5):. PubMed ID: 27796020
    [Abstract] [Full Text] [Related]

  • 28. Ultrasonographic renal volume measurements in early autosomal dominant polycystic disease: comparison with CT-scan renal volume calculations.
    Hammoud S, Tissier AM, Elie C, Pousset M, Knebelman B, Joly D, Hélénon O, Correas JM.
    Diagn Interv Imaging; 2015 Jan 09; 96(1):65-71. PubMed ID: 25547671
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E, Matschnig S, Lind P.
    Thyroid; 2006 Nov 09; 16(11):1113-9. PubMed ID: 17123338
    [Abstract] [Full Text] [Related]

  • 32. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
    Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT, DIPAK Consortium.
    Drug Saf; 2017 Feb 09; 40(2):153-167. PubMed ID: 27995519
    [Abstract] [Full Text] [Related]

  • 33. Volume regression of native polycystic kidneys after renal transplantation.
    Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, Cosio FG, El-Zoghby ZM, Torres VE.
    Nephrol Dial Transplant; 2016 Jan 09; 31(1):73-9. PubMed ID: 26044834
    [Abstract] [Full Text] [Related]

  • 34. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
    King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
    Kidney Int; 2003 Dec 09; 64(6):2214-21. PubMed ID: 14633145
    [Abstract] [Full Text] [Related]

  • 35. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    Liu YM, Shao YQ, He Q.
    Transplant Proc; 2014 Dec 09; 46(1):66-74. PubMed ID: 24507028
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report.
    Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, Remuzzi G, Remuzzi A.
    Clin J Am Soc Nephrol; 2006 Jul 09; 1(4):754-60. PubMed ID: 17699283
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
    Gevers TJ, Nevens F, Torres VE, Hogan MC, Drenth JP.
    Liver Int; 2016 Apr 09; 36(4):595-602. PubMed ID: 26481454
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.